Rights and permissions
About this article
Cite this article
Alendronic acid not cost effective for postmenopausal osteopenia. Pharmacoecon. Outcomes News 483, 6 (2005). https://doi.org/10.2165/00151234-200504830-00010
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200504830-00010